Curis Inc (FRA:CUS0)
€ 3.02 0.08 (2.72%) Market Cap: 26.40 Mil Enterprise Value: 9.52 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 41/100

Curis Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-recorded Transcript

Mar 09, 2021 / 12:00PM GMT
Release Date Price: €166 (+5.73%)
Stephen Bersey

Welcome, everyone. Thank you for joining us at the H.C. Wainwright 2021 Global Life Sciences Conference. My name is Stephen Bersey. I'm an equity research associate here at H.C. Wainwright.

Now I'd like to welcome our next presenter, James Dentzer, President and CEO of Curis. Curis is focused on the development and commercialization of drug candidates for the treatment of human cancers. So now I'll hand it over to James.

James E. Dentzer
Curis, Inc. - President, CEO & Director

Thank you, Stephen. Thank you for having us, really appreciate it. It's nice to be here today. I'm going to go through a general overview of Curis. I'll go through our corporate presentation deck, which I think you can see on-screen. I'm not going to belabor every single slide, but there are an awful lot of really exciting things going on at Curis. And I think in a brief period, we can go through the highlights.

So if I skip right to Slide 4. Slide 4 gives you a good overview of what makes Curis different compared to other companies in biotech. What we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot